Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00466856 · ClinicalTrials.gov registry record · Phase 2

Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors

A Phase 2 study, sponsored by Vanderbilt-Ingram Cancer Center.

Terminated
Registry status
Phase 2
Development phase
10
Enrollment target

NCT00466856 is a Phase 2 study that was terminated before completion, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 10 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00466856, a Phase 2 study, was terminated before completion, sponsored by Vanderbilt-Ingram Cancer Center.

TERMINATED
Registry status
Phase 2
Development phase
10 participants
Enrollment target

Study Summary

RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This phase II trial is studying how well internal radiation therapy works in treating patients with liver metastases from neuroendocrine tumors.

Interventions

  • DRUG octreotide acetate
  • RADIATION yttrium Y 90 resin microspheres

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2003-12
Est. Completion 2007-10
Phase Phase 2

Sponsor

Vanderbilt-Ingram Cancer Center

189 total trials

What the Registry Record Tells You About NCT00466856

The ClinicalTrials.gov registry entry for NCT00466856 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which octreotide acetate is the first listed.

NCT00466856 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00466856 about?

NCT00466856 is a clinical study titled "Internal Radiation Therapy in Treating Patients With Liver Metastases From Neuroendocrine Tumors". RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. PURPOSE: This phase II trial is studying how well internal radiation therapy works in treating patients with liver metastases from ...

What is the current status of trial NCT00466856?

This trial is currently terminated. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2003-12. Estimated completion is 2007-10.

What interventions are being tested in trial NCT00466856?

The interventions under investigation include: octreotide acetate (DRUG), yttrium Y 90 resin microspheres (RADIATION).

Who is sponsoring clinical trial NCT00466856?

This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.